NIIMBL (The National Institute for Innovation in Manufacturing Biopharmaceuticals)

NIIMBL’s Viral Vector Program has selected eight teams to participate in an interlaboratory study focused on improving the accuracy of AAV9 capsid titer measurements. The goal is to enhance consistency in manufacture of gene therapy products.

The selected teams are:

Last week, more than 400 representatives from the NIIMBL community joined in Washington, D.C. and virtually for the 2026 National Meeting. The meeting delivered the familiar mix of inspiring plenaries, expert‑led sessions, and member‑driven idea‑sharing that defines our annual event.

The program also highlighted standout contributions from across...

NIIMBL is pleased to announce “Inline Spiking Method for Validation of Virus Clearance in Continuous Bioprocessing” has been named the winner of NIIMBL’s inaugural Project Impact Award. The award is given annually as recognition of a Project Call Project exemplifying technical ingenuity, partnership and lasting industry impact. The award will be...